The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Open accessAbstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. OBJECTIVE: Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2). METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score. Secondary end points included change from baseline to week 24 in Sino-Nasal Outcome Test-22 (SNOT-22) score, University of Pennsylvania Smell Identification Test, sense of smell, postnasal drip, runny nose, and adverse events. RESULTS: Patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) exhibited severe CRSwNP and substantial quality of life impairment evidenced by a mean NPS higher than 6 and SNOT-22 score of approximately 60. Both studies met both the coprimary end points. SNOT-22 score, University of Pennsylvania Smell Identification Test score, sense of smell, postnasal drip, and runny nose were also significantly improved for omalizumab versus placebo. In POLYP 1 and POLYP 2, the mean changes from baseline at week 24 for omalizumab versus placebo were as follows: NPS, -1.08 versus 0.06 (P < .0001) and -0.90 versus -0.31 (P = .0140); Nasal Congestion Score, -0.89 versus -0.35 (P = .0004) and -0.70 versus -0.20 (P = .0017); and SNOT-22 score, -24.7 versus -8.6 (P < .0001) and -21.6 versus -6.6 (P < .0001). Adverse events were similar between groups. CONCLUSION: Omalizumab significantly improved endoscopic, clinical, and patient-reported outcomes in severe CRSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citationPsychometric validity of the 22‐item Sinonasal Outcome Test
Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01995.x · Cited by 1,621
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · cited 1×
“2.(24,29,30) The full analysis set (FAS) included all randomized patients who received at least 1 dose of study drug according to assigned treatment group.”
Self-citationOmalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Self-citationNovel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study
Tokunaga, T., Sakashita, M., Haruna, T., Asaka, D., Takeno, S., Ikeda, H., Nakayama, T., Seki, N., Ito, S., Murata, J., et al. (2015) · Allergy · doi:10.1111/all.12644 · Cited by 710
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Self-citationChronic Rhinosinusitis with Nasal Polyps
Stevens, W. W., Schleimer, R. P., & Kern, R. C. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2016.04.012 · Cited by 571
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
DeConde, A. S., Mace, J. C., Levy, J. M., Rudmik, L., Alt, J. A., & Smith, T. L. (2017) · The Laryngoscope · doi:10.1002/lary.26391 · Cited by 443
Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper
Kowalski, M. L., Agache, I., Bavbek, S., Bakirtas, A., Blanca, M., Bochenek, G., Bonini, M., Heffler, E., Klimek, L., Laidlaw, T. M., et al. (2019) · Allergy · doi:10.1111/all.13599 · Cited by 360
Self-citationCost of adult chronic rhinosinusitis: A systematic review
Smith, K. A., Orlandi, R. R., & Rudmik, L. R. (2015) · The Laryngoscope · doi:10.1002/lary.25180 · Cited by 354
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis
Bachert, C., Zhang, L., & Gevaert, P. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.010 · Cited by 317
Self-citationEconomics of Chronic Rhinosinusitis
Rudmik, L. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0690-5 · Cited by 270
Dietz de Loos, D., Lourijsen, E. S., Wildeman, M. A. M., Freling, N. J. M., Wolvers, M. D. J., Reitsma, S., & Fokkens, W. J. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.12.986 · Cited by 268
Calus, L., Van Bruaene, N., Bosteels, C., Dejonckheere, S., Van Zele, T., Holtappels, G., Bachert, C., & Gevaert, P. (2019) · Clinical and Translational Allergy · doi:10.1186/s13601-019-0269-4 · Cited by 210
Self-citationMucosal tissue polyclonal IgE is functional in response to allergen and SEB
Zhang, N., Holtappels, G., Gevaert, P., Patou, J., Dhaliwal, B., Gould, H., & Bachert, C. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02448.x · Cited by 194
Self-citationChowdhury, N. I., Mace, J. C., Bodner, T. E., Alt, J. A., Deconde, A. S., Levy, J. M., & Smith, T. L. (2017) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22028 · Cited by 173
Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps
Gevaert, P., Nouri‐Aria, K. T., Wu, H., Harper, C. E., Takhar, P., Fear, D. J., Acke, F., De Ruyck, N., Banfield, G., Kariyawasam, H. H., et al. (2013) · Allergy · doi:10.1111/all.12054 · Cited by 162
Self-citationBenjamin, M. R., Stevens, W. W., Li, N., Bose, S. K., Grammer, L. C., Kern, R. C., Tan, B. K., Conley, D. B., Smith, S. S., Welch, K. C., et al. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.10.014 · Cited by 148
Symptoms of chronic rhinosinusitis differentially impact general health-related quality of life
Hoehle, L. P., Phillips, K. M., Bergmark, R. W., Caradonna, D. S., Gray, S. T., & Sedaghat, A. R. (2016) · Rhinology journal · doi:10.4193/rhino16.211 · Cited by 147
Real-life long-term omalizumab therapy in children with severe allergic asthma
Deschildre, A., Marguet, C., Langlois, C., Pin, I., Rittié, J. L., Derelle, J., Taam, R. A., Fayon, M. J., Brouard, J., Dubus, J. ‐., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00008115 · Cited by 131
The Role of Staphylococcus aureus in Patients with Chronic Sinusitis and Nasal Polyposis
Vickery, T. W., Ramakrishnan, V. R., & Suh, J. D. (2019) · Current Allergy and Asthma Reports · doi:10.1007/s11882-019-0853-7 · Cited by 129
Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications
Schryver, E. D., Devuyst, L., Derycke, L., Dullaers, M., Zele, T. V., Bachert, C., & Gevaert, P. (2015) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2015.7.4.321 · Cited by 124
Self-citationKhan, A. H., Huynh, T. M. T., Vandeplas, G., Joish, V. N., Mannent, L. P., Tomassen, P., Zele, T. V., Cardell, L., Arebro, J., Olze, H., et al. (2019) · Rhinology Journal · doi:10.4193/rhin19.158 · Cited by 123
Self-citationLai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., et al. (2015) · Scientific Reports · doi:10.1038/srep08191 · Cited by 103
Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study
Bidder, T., Sahota, J., Rennie, C. E., Lund, V. J., Robinson, D. S., & Kariyawasam, H. H. (2017) · Rhinology Journal · doi:10.4193/rhin17.139 · Cited by 100
Efficacy of omalizumab in the treatment of nasal polyps
Vennera, M. D. C., Picado, C., Mullol, J., Alobid, I., & Bernal‐Sprekelsen, M. S. (2010) · Thorax · doi:10.1136/thx.2010.152835 · Cited by 99
Self-citationThe XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
Maurer, M., Kaplan, A. P., Rosén, K. E., Holden, M., Iqbal, A., Trzaskoma, B. L., Yang, M., & Casale, T. B. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.018 · Cited by 92
Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients
Siergiejko, Z., Świebocka, E., Smith, N., Peckitt, C., Leo, J., Peachey, G., & Maykut, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.620950 · Cited by 84
Le, P. T., Soler, Z. M., Jones, R., Mattos, J. L., Nguyen, S. A., & Schlosser, R. J. (2018) · Otolaryngology · doi:10.1177/0194599818773065 · Cited by 84
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics
Lieberman, P. L., Jones, I., Rajwanshi, R., Rosén, K. E., & Umetsu, D. T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.013 · Cited by 81
Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities
Koennecke, M., Klimek, L., Mullol, J., Gevaert, P., & Wollenberg, B. (2018) · Allergo Journal International · doi:10.1007/s40629-017-0048-5 · Cited by 76
Self-citationBhutani, M., Yang, W. H.-C., Hébert, J., de Takacsy, F., & Stril, J.-L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183869 · Cited by 57
Naclerio, R. M., Baroody, F. M., Bachert, C., Bleier, B. S., Borish, L., Brittain, E., Chupp, G. L., Fisher, A., Fokkens, W. J., Gevaert, P., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.023 · Cited by 56
Self-citationTakeda, K., Sakakibara, S., Yamashita, K., Motooka, D., Nakamura, S., Hussien, M. A. E., Katayama, J., Maeda, Y., Nakata, M., Hamada, S., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.006 · Cited by 52
A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain
Ye, Z., Sun, L., & Wang, Q. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1137-6 · Cited by 48
Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population
Staniorski, C., Price, C. P. E., Weibman, A. R., Welch, K. C., Conley, D. B., Smith, S. S., Stevens, W. W., Peters, A. T., Grammer, L. C., Lidder, A. K., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22064 · Cited by 46
Erskine, S. E., Hopkins, C. L., Kumar, N., Wilson, J. A., Clark, A., Robertson, A., Kara, N., Sunkaraneni, V., Anari, S., & Philpott, C. M. (2016) · Rhinology Journal · doi:10.4193/rhino15.361 · Cited by 37
Cited by
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
Self-citationHan, J. K., Bachert, C., Fokkens, W., Desrosiers, M., Wagenmann, M., Lee, S. E., Smith, S. G., Martin, N., Mayer, B., Yancey, S. W., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00097-7 · Cited by 628
Self-citationChronic Rhinosinusitis with Nasal Polyps and Asthma
Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N., & Mannent, L. P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.063 · Cited by 419
Self-citationBachert, C., Han, J. K., Wagenmann, M., Hosemann, W., Lee, S. E., Backer, V., Mullol, J., Gevaert, P., Klimek, L., Prokopakis, E., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.013 · Cited by 355
Self-citationBachert, C., Marple, B., Schlosser, R. J., Hopkins, C., Schleimer, R. P., Lambrecht, B. N., Bröker, B. M., Laidlaw, T., & Song, W.-J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00218-1 · Cited by 327
Self-citation
Metadata
- Authors
- Gevaert, P., Omachi, T. A., Corren, J., Mullol, J., Han, J., Lee, S. E., Kaufman, D., Ligueros-Saylan, M., Howard, M., Zhu, R., Owen, R., Wong, K., Islam, L., & Bachert, C.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 146
- Issue
- 3
- Pages
- 595-605
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3034146395
- Cited by
- 739
- References
- 39
- FWCI
- 71.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.